Remote Centralized Ratings

By: Medavante  06-Dec-2011
Keywords: Value Proposition

Centralizing our raters and managing them in real time makes it technically feasible to continuously train, monitor, and calibrate the entire rater cohort. This level of standardization is not logistically feasible with a large group of raters in unconnected study sites.

  • The higher the ICC, the higher the study power and the lower the sample size required

MedAvante’s Remote Centralized Ratings service addresses issues of baseline score inflation and expectancy bias by providing the services of expert, clinical raters working remotely from a central location.

Centralized remote expert raters continuously train to highest inter-rater reliability (ICC) in industry

  • Remote central expert raters are "blind" to enrollment criteria and uninfluenced by familiarity with the site, visit order and patient expectations

The results of centralized and calibrated expert raters are impressive:

  • Delivers the patient population - and maintains it - exactly as in protocol
  • Gain access to subjects at investigative sites without CNS professionals
  • Reduce overall number of raters employed to reduce variability
  • Enable highest possible quality control throughout study
  • Ensure highest possible reliability, accuracy - without any drift
  • Increase study power or enable smaller sample size
  • Enhance signal detection and separation of drug from placebo 

The result for sponsors is the highest level of certainty in maximizing the value proposition for their CNS products and delivering effective therapies for treating debilitating CNS diseases.

Remote Centralized Ratings coupled with CQC is an ideal solution for a global clinical trial.

Keywords: Value Proposition

Contact Medavante

Email - none provided

Print this page

Other products and services from Medavante


MedAvante Products & Services

Sponsors of CNS clinical trials can select precisely the level of service needed to achieve their goals for signal detection, study power, and inter-rater reliability. Toward that end, MedAvante offers four levels of service, each based on our highly precise methodology for increasing objectivity in CNS studies. MedAvante is dedicated to bringing certainty to the mental-health evaluations and assessments performed during CNS clinical trials.


MedAvante: Solutions

By applying this methodology, MedAvante overcomes the major threat to achieving signal detection: Issues with the trial assessments’ validity and reliability caused by biases and interviewer variability. An entire cohort of study raters comprised of high quality interviewers can still result in poor reliability for the study as a whole, with an attendant negative effect on study power.


Continuous Quality Control Monitoring Service

Provides own score of interview scale: automated workflow program will not provide site's scores until MedAvante expert trainer enters their assessment scores. MedAvante expert trainers are calibrated to provide consistent feedback to all site raters to minimize rater variability. Site-based raters digitally record all their subject interviews through provided laptop. Calibrate the site raters to the central MedAvante expert trainer cohort.


MedAvante Patient Ascertainment

MedAvante can dramatically improve the accuracy of patient ascertainment by employing a bank of centralized calibrated expert raters to qualify patient enrollment during the initial screening process. By enrolling the right subject and accurately assessing their baseline symptom severity, MedAvante Patient Ascertainment service increases objectivity in CNS clinical trials.


MedAvante Rater ReadinessTraining

To provide the highest levels of rater training, MedAvante offers enriched Rater Readiness training, a superior approach that puts extraordinary emphasis on the rater's applied interviewing skills which is representative of real world trial conditions. The result can be greater certainty in maximizing the value proposition for CNS products and delivering effective therapies for treating debilitating CNS diseases.